Blood biogenic amines during clozapine treatment of early-onset schizophrenia

Journal of Neural Transmission

Volumn 104, Issue 10, 1997, Pages 1077-1089

  Schulz, E ^a   Fleischhaker, C ^a   Clement, H W ^a   Remschmidt, H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Clozapine; Early onset; Epinephrine; Human; Norepinephrine; Schizophrenia; Serotonin

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENALIN; BIOGENIC AMINE; CLOZAPINE; NEUROLEPTIC AGENT; NORADRENALIN; SEROTONIN;

ADOLESCENT; ADRENALIN BLOOD LEVEL; ADULT; BIOCHEMISTRY; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; FEMALE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCHOOL CHILD; SEROTONIN BLOOD LEVEL; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; BIOGENIC AMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; TIME FACTORS;

EID: 0031435394     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01273320     Document Type: Conference Paper

References (52)

1. Ackenheil M (1989) Clozapine: pharmacokinetic investigations and biochemical effects in man. Psychopharmacol 99: 32-37
2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Association, Washington
3. Andreasen NC (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784-788
4. Andreasen NC (1984a) The Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City
5. Andreasen NC (1984b) The Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City
6. Andreasen NC, Flaum M, Arndt S, Alliger R, Swayze VW (1991) Positive and negative symptoms: assessment and validity. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 28-51
7. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm [Gen Sect] 85: 19-29
8. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry [Suppl]: 12-16
9. Banki CM (1978) Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid and total blood serotonin content during clozapine treatment. Psychopharmacol 56: 195-198
10. Birmaher B, Baker R, Kapur S, Quintana H, Ganguli R (1992) Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiat 31: 160-164
11. Blanz B, Schmidt MH (1993) Clozapine for schizophrenia. J Am Acad Child Adolesc Psychiat 32: 223-224
12. Boomsma F, Alberts G, Vaneijk L, Manintveld AJ, Schalekamp MADH (1993) Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. Clin Chem 39: 2503-2508
13. Breier A (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14: 187-202
14. Breier A, Buchanan RW, Waltrip RW, Listwak S, Holmes G, Goldstein DS (1994) The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacol 10: 1-7
15. Brunello N, Masotto, C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacol 13: 177-213
16. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486
17. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL (1994) An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiat 33: 658-663
18. Ganhao MF, Hattingh J, Hurwitz ML, Pitts NI (1991) Evaluation of a simple plasma catecholamine extraction procedure prior to high-performance liquid chromatography and electrochemical detection. J Chromatogr 564: 55-66
19. Gordon CT, Frazier JA, McKenna K, Giedd J, Zametkin A, Zahn T, Hommer D, Hong W, Kaysen D, Albus KE, Rapoport JL (1994) Childhood-onset schizophrenia: an NIMH study in progress. Schizophr Bull 20: 697-712
20. Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ (1993) Clozapine response and plasma catecholamines and their metabolites. Psychiat Res 46: 139-149
21. Kahn RS, Davidson M (1993) On the value of measuring dopamine, norepinephrine and their metabolites in schizophrenia. Neuropsychopharmacol 8: 93-95
22. Kapur S, Remington G (1996) Serotonin-dopamine interaction and ist relevance to schizophrenia. Am J Psychiatry 153: 466-476
23. Kroesen S, Marksteiner J, Mahata M, Fischer Colbrie R, Saria A, Kapeller I, Winkler H (1995) Effects of haloperidol, clozapine and citalopram on messenger RNA levels of chromogranins A and B and secretogranin II in various regions of rat brain. Neurosci 69: 881-891
24. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA (1995) Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 152: 179-182
25. Lake CR, Ziegler MG (1985) Techniques for the assessment and interpretation of catecholamine measurements in neuropsychiatric patients. In: Lake CR, Ziegler MG (eds) The catecholamines in psychiatric and neurologic disorders. Butterworth Publishers, Stone-Hane, pp 1-34
26. Lesch KP, Wolzin BL, Murphy DL, Riederer P (1993) Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 60: 2319-2322
27. Lieberman JA, John C, Pollack S, Masier S, Bookstein P, Cooper T, Iadorola M, Kane J (1991) Biochemical effects of clozapine in cerebrospinal fluid of patients with schizophrenia. In: Tamminga CA, Schulz S (eds) Schizophrenia research, vol 1. Raven Press, New York, pp 341-349
28. Meszaros K, Lenzinger E, Fureder T, Hornik K, Willinger LJ, Stompe T, Heiden AM, Resinger E, Fathi N, Gerhard E, Fuchs K, Miller-Reiter E, Pfersmann V, Sieghart W, Aschauer HN, Kasper S (1996) Schizophrenia and the dopamine beta hydroxylase gene: results of a linkage and association study. Psychiatr Genet 6: 17-22
29. Miller DD, Fleming F, Holman T, Perry PJ (1994) Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiat 55: 117-121
30. Moscarelli M, Maffei C, Cesana BM, Boato B (1987) An international perspective on assessment of negative and positive symptoms in schizophrenia. Am J Psychiatry 144: 1595-1598
31. Mozes T, Toren P, Chernauzan N, Mester R, Yoranhegesh R, Blumensohn R, Weizman A (1994) Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiat 33: 65-70
32. 3H]paroxetine. J Neural Transm 103: 749-757
33. Orellana-Vidal GP (1995) Locus coeruleus: implications for psychiatry. Acta Psiquiat Psicol Am Lat 41: 57-66
34. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10: 799-812
35. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH (1992) Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 49: 345-353
36. Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT, Rapoport JL (1994) Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia-association with response. J Clin Psychiatry 55: 94-97
37. Pluto R, Bürger P (1988) Normal values of catecholamines in blood plasma determined by high-performance liquid chromatography with amperometric detection. Int J Sports Med 9: 75-78
38. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55: 133-136
39. Remschmidt H, Martin M, Schulz E, Gutenbrunner C, Fleischhaker C (1991) The concept of positive and negative schizophrenia in child and adolescent psychiatry. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 219-242
40. Remschmidt H, Schulz E, Martin M (1992) Die Behandlung schizophrener Psychosen in der Adoleszenz mit Clozapine (Leponex). In: Naber D, Müller-Spahn F (Hrsg) Clozapine. Pharmakologie und Klinik eines atypischen Neuroleptikums. Schattauer, New York, S 99-119
41. Remschmidt H, Schulz E, Martin M (1994a) An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 4: 31-41
42. Remschmidt H, Schulz E, Martin M, Warnke A, Trott GE (1994b) Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull 20: 727-745
43. Riederer P, Laux G (1992) Therapeutic drug monitoring of psychotropics: report of a consensus conference. Pharmacopsychiat 25: 271-272
44. Schulz E, Fleischhaker C, Remschmidt H (1995) Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiat 28: 20-25
45. Schulz E, Fleischhaker C, Remschmidt H (1996) Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol 6: 119-131
46. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275: 101-113
47. Siefen G, Remschmidt H (1986) Behandlungsergebnisse mit Clozapine bei schizophrenen Jugendlichen. Z Kinder Jugendpsychiat 14: 245-257
48. Towbin KE, Dykens EM, Pugliese RG (1994) Clozapine for early developmental delays with childhood-onset schizophrenia - protocol and 15-month outcome. J Am Acad Child Adolesc Psychiat 33: 651-657
49. van Kammen DP (1991) The biochemical basis of relaps and drug response in schizophrenia: review and hypothesis. Psychol Med 21: 881-895
50. van Kammen DP, Kelley M (1991) Dopamine and norepinephrine activity in schizophrenia. An integrative perspective. Schizophr Res 4: 173-191
51. Weier TB, Smith CT, Round JM, Betteridge DJ (1986) Stability of catecholamines in whole blood, plasma, and platelets. Clin Chem 32: 822-833
52. Yamamoto K, Ozawa N, Shinba T, Hoshino T, Yoshii M (1994) Possible noradrenergic dysfunction in schizophrenia. Brain Res Bull 35: 529-543